Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course latent tuberculosis infection treatment in people with prior pulmonary tuberculosis
ChiCTR1800018224Phase 4Recruiting
- Sponsor
- Institute of Pathogen Biology
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid and rifapentine in latent tuberculosis infection (LTBI) (2 arms), sponsored by Institute of Pathogen Biology. Primary endpoint: Diagnosis of active pulmonary tuberculosis. Started Sep 2018; status: recruiting.
02
Drugs
isoniazidrifapentine
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ChiCTR1800018224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018224.